Senseonics (NYSE:SENS) announced today that it entered into an agreement with Ascensia Diabetes Care to take over commercialization efforts for its products. The companies entered into a mutually executed memorandum of understanding. This agreement transitions all commercialization and distribution of the Eversense 365 long-term implantable continuous glucose monitor (CGM) and future products from Ascensia to […]
Ascensia Diabetes Care
Senseonics lays out hopes for next-gen CGM commercial timelines
Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes Association’s 85th Scientific Sessions in Chicago this past weekend. At that event, the company touched on the commercial strategy for Eversense […]
Senseonics expects to double global patient base in 2025, progresses with pump integration
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of SENS went up nearly 7% to 93¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $15.5 million for the quarter. That equals losses 2¢ per […]
Ascensia Diabetes Care creates “wellness zone” for World Diabetes Day
Ascensia Diabetes Care today announced its plans to recognize World Diabetes Day 2024 with a virtual diabetes campaign. World Diabetes Day — Nov. 14 — recognizes the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. November is also the American Diabetes Association’s National Diabetes Awareness Month. […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S. Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older. Senseonics announced last month that it received FDA clearance for Eversense 365. With […]
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]
The steps ahead for the Eversense implantable CGM platform
As Senseonics and Ascensia Diabetes Care looked for someone to help scale their CGM business, they turned to someone had only just retired. After close to eight years as Tandem Diabetes Care CCO, Brian Hansen notified the company of his decision to step down last August. His final day landed on Dec. 31, but he […]
Senseonics wins integrated CGM designation from FDA, can work with insulin pumps
The FDA today granted integrated CGM (iCGM) designation to the Eversense continuous glucose monitoring system from Senseonics (NYSE:SENS). With this designation, Eversense becomes the first fully implantable device in the category. Senseonics can now market the long-term CGM through the FDA’s de novo pathway. This establishes the special controls serving as a predicate device for […]
Ascensia, Senseonics announce new CGM cost savings
Ascensia Diabetes Care and Senseonics today announced an extension to their Eversense Payment Assistance and Simple Savings (PASS) program. The program aims to help people in the U.S. access the Eversense E3 continuous glucose monitor (CGM) more affordably. It offers major savings for eligible individuals looking to experience the benefits of the long-term, implantable CGM. […]
